Gilead Reaches Number One Spot as Top Overall Philanthropic Funder of HIV-Related Programs, According to Funders Concerned About AIDS Report

Press Release

FOSTER CITY, Calif., May 25, 2022 /3BL Media/ Gilead Sciences, Inc. (Nasdaq: GILD) was officially recognized as the number one philanthropic funder of HIV-related programs in a new tracking report released by Funders Concerned About AIDS (FCAA). The report, found at: https://www.fcaaids.org/inform/philanthropic-support-to-address-hiv-aids/, is released annually and is widely regarded as the most comprehensive study of its kind.

Gilead at Forefront of Herculean Effort to Combat COVID-19


In the winter 2019, Kavita Juneja found herself at the center of a maelstrom. A strange and deadly virus known as SARS-CoV-2 was hurtling across the globe.

“We saw the magnitude of the pandemic as it immediately swept globally from China to Europe,” says Kavita, Gilead’s Senior Director, Clinical Development, Virology. “It was surreal and really something to witness. We knew it was going to spread globally and asked ourselves if we were going to be prepared.”

Living with Metastatic Bladder Cancer: Joey's Journey

Multimedia with summary

Joey sold his business and felt like he was living the American dream when his life was turned upside down in 2019. He was diagnosed with metastatic bladder cancer.

“I remember I was trying to call my wife to talk to her,” recalls Joey. “And then I couldn't speak.”

Playwright Lee Raines Shines a Spotlight on the Criminalization of HIV


The day after Lee Raines found out he acquired HIV, he was arrested by police in New York. It was 1989, and he was one of thousands of people who attended a protest against New York City’s policy to fight the HIV epidemic – a policy that protesters believed was inadequate. More than 200 people were arrested.

Lee was released from custody after a few hours, but the experience had a profound impact on him.

“I came out stumbling,” he says. “It was a sliver of what incarceration is, but I realized suddenly that this is everyday life for a lot of Americans.”

Gilead Sciences Presents at ECCMID 2022 - Continues Mission to Advance Access to Effective Therapies

Multimedia with summary

The data we presented at ECCMID 2022 is part of Gilead’s mission to advance access to effective therapies. We've helped transform the treatment and prevention of HIV and delivered HCV cures as a result of our deep scientific understanding of viruses and expertise in antiviral drug development.

View original content here.

On Earth Day, Gilead Marks Strides in Environmental Sustainability

Multimedia with summary

This Earth Day, we’re highlighting our longstanding commitment to environmental stewardship. We’ll continue to accelerate our efforts to reduce greenhouse gas emissions, minimize waste generation and operate responsibly – all in an effort to protect our planet.

View original content here.

Opinion: The Road to Ending Visceral Leishmaniasis

By Aida Meskel

Visceral leishmaniasis, or VL, is a parasitic disease that is spread via sand flies. If left untreated, VL kills 95% of its victims. Endemic in 78 countries and territories, it is the second-deadliest parasitic disease after malaria and presents as a fever, weight loss, enlargement of the spleen and liver, and anemia.

Closing the Representation Gap in Schools, One Black Male Teacher at a Time


Codion Isom never had any teachers who looked like him growing up, and as a Black man he knows the importance of having Black male role models at a young age. That’s why he answered the call to play that role when he got older.

“I was doing security work in Texas, two years out of college, when I got an email from a former professor about Urban Ed Academy,” Codion recalls. “It asked, ‘How many Black male teachers have you had?’ That’s when I realized this might be something I need to do.”

Gilead Sciences Announces Support for the Robert A. Winn Diversity in Clinical Trials Award Program

Multimedia with summary

Today we announced our support of the Robert A. Winn Diversity in Clinical Trials Award Program, a five-year initiative launched by the Bristol Myers Squibb Foundation to increase diversity in clinical trials. 

The Translatinx Network Helps a Resilient Community 'Live Its Truth'


When Cristina Herrera was 15 years old, she traveled alone from Southern California to the Bronx in pursuit of new life experiences. A native of El Salvador, Cristina thought as a teenager that she was different, but she was unsure about which terminology fully captured her identity.

“I knew that I wasn't gay,” explains Cristina. “But I couldn’t put into words as to who I was.” 

It was only through connecting with the trans Latinx community in New York that Cristina found herself – and came out as transgender.


Subscribe to NYSE:GILD